Barchart.com
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
4.61 x 4 4.67 x 5
Post-market by (Cboe BZX)
4.57 +0.11 (+2.47%) 04/14/25 [NASDAQ]
4.61 x 4 4.67 x 5
Post-market 4.61 +0.04 (+0.88%) 19:58 ET
News & Headlines for Mon, Apr 14th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings GlobeNewswire - Thu Apr 10, 3:02PM CDT

ARDX : 4.57 (+2.47%)
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings GlobeNewswire - Mon Mar 31, 3:03PM CDT

ARDX : 4.57 (+2.47%)
Doctor holding money by IherPhoto via iStock
2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102% Barchart - Thu Mar 20, 12:55PM CDT

These smaller stocks may carry more risk, but they also carry greater reward potential.

NVDA : 110.71 (-0.20%)
BAYRY : 5.9500 (+0.85%)
RXRX : 5.51 (-4.34%)
ARDX : 4.57 (+2.47%)
RHHBY : 38.2700 (+0.45%)
SNY : 51.84 (+0.66%)
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award GlobeNewswire - Thu Mar 13, 7:02AM CDT

ARDX : 4.57 (+2.47%)
Tenapanor Approved in China for Hyperphosphatemia GlobeNewswire - Wed Feb 26, 6:00AM CST

ARDX : 4.57 (+2.47%)
Ardelyx to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Feb 25, 3:15PM CST

ARDX : 4.57 (+2.47%)
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism Stocktwits - Thu Feb 20, 9:44PM CST

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

VTI : 264.15 (+0.92%)
ARDX : 4.57 (+2.47%)
IWM : 186.53 (+1.18%)
XBI : 76.54 (+2.97%)
Ardelyx Tops Estimates as Sales Surge Motley Fool - Thu Feb 20, 12:58PM CST

The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.

ARDX : 4.57 (+2.47%)
Ardelyx: Q4 Earnings Snapshot AP - Thu Feb 20, 6:52AM CST

Ardelyx: Q4 Earnings Snapshot

ARDX : 4.57 (+2.47%)
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 20, 6:30AM CST

ARDX : 4.57 (+2.47%)

Barchart Exclusives

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty Barchart - Mon Apr 14, 6:30PM CDT
These companies offer consistent dividend growth and a strong industry presence. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot